November 28, 2006 -- Artes Medical, a dermatology company, will offer 4.6 million shares in a $12-$14 range in its IPO; Cytokinetics will amend its agreement with GlaxoSmithKline, assuming development costs for two cancer drugs; Millennium will begin a double-blind Phase II trial of an arthritis treatment; Alnylam began human testing of its respiratory syncytial virus drug, which is based on RNA interference technology; Neurogen in-licensed a Parkinson’s disease drug from Wyeth; and Pfizer will opt out of a schizophrenia collaboration with Organon. The Centient Biotech 200™ rose a modest 8 points to 3939, an increase of .22%. More details...
